Retrospective study designed to evaluate outcomes in patients undergoing assisted reproduction. Some of them had thrombophilia, and part of them was treated with enoxaparin, started on the day of embryo transfer, and the other part not. Women without thrombophilia formed the control group.
A retrospective study was performed to evaluate the results in 104 patients undergoing to assisted reproduction. Women without thrombophilia were included as controls (n=20), while women with thrombophilia were either treated with 40 mg daily of enoxaparin (treated group, n=54), initiated on the day of embryo transfer, and continued to the week 36 of gestation, or did not receive this medication (untreated group, n= 30).
Study Type
OBSERVATIONAL
Enrollment
104
Women with thrombophilia were treated with 40 mg daily of enoxaparin (treated group), initiated on the day of embryo transfer, up to week 36 of gestation
Assistencia Materno Infantil Lambert
Santo André, São Paulo, Brazil
Number of participants with detectable fetal heartbeat
A transvaginal ultrasound was performed for detection of fetal heartbeat
Time frame: Day 28
Number of participants with detectable ongoing pregnancy
Ongoing pregnancy was detected by ultrasound at twelve weeks
Time frame: Week 12
Number of participants who delivered a live baby
Live birth was considered delivery that resulted in at least one live born neonate
Time frame: Week 36
Number of participants with biochemical gestation detected
Serum beta-HCG detected 14 days after embryo transfer
Time frame: Day 14
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.